How AmSurg went from bankruptcy to a $3.9B Ascension deal

 AmSurg’s history is unlike the other major ASC chains, shaped by a series of massive ownership transformations reshaping its identity and risk profile. 

Starting as the pioneer of the physician-partnership ASC model, it stretched into physician services via Sheridan, merged into a $10 billion diversified company with Envision, became buried under PE debt, survived Envision’s bankruptcy as a standalone entity and is now landing under a nonprofit health system for what its leaders call its next chapter.

Here’s a breakdown of AmSurg’s last 30 years: 

Origins and early dominance 

AmSurg’s roots trace to a consulting firm. Co-founders David Manning and Rodney Lunn began as ASC consultants in 1986, eventually forming AmSurg in 1992 with backing from Nashville-area investors. The company went public in 1997, and by 2002, AmSurg had reached 100 ASCs and briefly claimed the title of largest ASC provider in the U.S. 

AmSurg’s ownership model distinguished it from the outset. The company held 51% of each center while physicians retained 49%, a structure that aligned incentives and became a defining competitive feature.

2014-2015: The Sheridan acquisition — from ASC operator to physician services company

In 2014, AmSurg acquired Sheridan Healthcare in a $2.35 billion deal funded with $615 million of equity and the remainder in debt, adding more than 4,600 physician relationships in 38 states and expanding its footprint into anesthesiology, radiology and emergency medicine.

Financially, AmSurg’s net revenues increased 53% from 2014 to $1.62 billion in 2015, primarily due to Sheridan’s financial results, and the company continued acquiring anesthesia and radiology groups throughout the year.

2016: The Envision mega-merger

In 2016, AmSurg merged with Envision Healthcare in a $10 billion all-stock deal, creating a combined healthcare services company spanning ASCs and physician services.The resulting entity, operating under the Envision Healthcare name, was heavily weighted toward physician services. 

After the merger, physician services accounted for 81% of Envision’s core revenues, with the company acquiring nine physician practices in the first half of 2016 alone for $440.8 million.

2018: KKR’s $9.9 billion acquisition

Two years after the Envision merger, the combined company was taken private. KKR completed its $9.9 billion acquisition of Envision Healthcare, making Envision a wholly-owned subsidiary. Following the acquisition, the combined Envision/AmSurg entity had about 300 ASCs in its portfolio.

Notably, Envision rejected two of KKR’s offers before accepting the final $9.9 billion bid, which underscores how contested the valuation was at the time. The deal was financed with more than $7 billion in debt, a structure that would become increasingly difficult to sustain as interest rates and labor costs rose.

2019-2022: Debt pressure 

The KKR years were defined by the financial strain of the leveraged buyout. While AmSurg’s ASC operations continued steadily — the number of AmSurg ASCs grew 17% since 2011, reaching approximately 250 centers across 34 states with about 2,000 physicians — the parent company Envision was faltering under its debt load and deteriorating relationships with insurers. The pandemic added further pressure on volumes, and rising interest rates made the debt structure increasingly untenable. 

2023: Envision bankruptcy & AmSurg’s split

In May 2023, Envision filed for Chapter 11 bankruptcy protection, citing pressures including rising interest rates, labor costs and payment disputes with insurers. 

AmSurg split from Envision in October 2023 and purchased all of the ASCs held by Envision, emerging as a separate and independent entity with 250 surgery centers across 34 states. Pacific Investment Management Co., a creditor, became AmSurg’s new majority owner following the restructuring.

With Jeff Snodgrass installed as CEO, the company began rebuilding as a standalone operation and quickly resumed acquisition activity — picking up centers in Oregon, Las Vegas, Maryland and California in the months following the split.

2024-2025: Rebuilding the platform 

Post-independence, AmSurg’s strategy centered on broadening what had always been a relatively GI- and ophthalmology-heavy portfolio. AmSurg focused on diversifying its portfolio mix, broadening service lines, expanding health system partnerships, reinforcing its commitment to independent physician practices and enhancing its management company value proposition to optimize surgery center performance for patients, partners and payers.

The company leaned into a “collaborative model” that distinguished it from more acquisitive peers. AmSurg controls roughly 3.9% of the ASC market with 250-plus ASCs across 34 states and partners with about 2,000 physicians. New joint ventures with health systems like LifeBridge Health and Palomar Health illustrated growth through partnership rather than pure acquisition.

2025-2026: Pending Ascension acquisition

AmSurg’s next chapter came in mid-2025 when another major ownership change arrived — this time to Ascension rather than a PE firm. The transaction, valued at about $3.9 billion and expected to close in late 2025 or early 2026, would expand Ascension’s ASC footprint from 58 to more than 300 centers across 34 states.

Ascension CEO Joe Impicciche positioned the acquisition as mission-aligned, expanding access to affordable, localized care while enhancing capacity for procedures rapidly shifting out of hospitals, such as orthopedics and cardiology. AmSurg’s leadership framed the deal as an accelerant, not a disruption. Mr. Snodgrass told Becker’s the company had invested heavily in its team and culture and described the organization as “very mission focused,” adding that the Ascension acquisition would “only advance and accelerate” those objectives.

https://www.beckershospitalreview.com/finance/bankruptcy-pe-debt-and-a-3-9b-ascension-deal-a-30-year-breakdown-of-amsurg/